Pulse Entdecken nav.journalClub Debatten Trends Forschende Zeitschriften

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Start Entdecken nav.journalClub Trends

⌘+K

SGLT2 Inhibitor Use and Cardiorenal Outcomes in Type 2 Diabetes With Liver Cirrhosis | Synapse

February 25, 2026JAMA Network Open0 citationsOpen Access

View Full Paper

SGLT2 Inhibitor Use and Cardiorenal Outcomes in Type 2 Diabetes With Liver Cirrhosis

MCMu-Chi Chung TYTung-Min Yu LWLaing-You Wu

Key Points

This cohort study aims to evaluate the impact of SGLT2 inhibitors on kidney, cardiovascular, and hepatic outcomes in patients with type 2 diabetes and liver cirrhosis.
Cohort study design
Patients included were those with type 2 diabetes and liver cirrhosis
Comparison of SGLT2 inhibitors and DPP4 inhibitors
SGLT2 inhibitors were linked to lower risks of kidney-related issues
SGLT2 inhibitors significantly reduced cardiovascular complications
Patients using SGLT2 inhibitors had better hepatic outcomes compared to those on DPP4 inhibitors

Abstract

In this cohort study of patients with T2D and liver cirrhosis, the use of SGLT2is was associated with substantially lower risks of adverse kidney, cardiovascular, and hepatic outcomes compared with DPP4is. These findings suggested significant cardiorenal and hepatic protection for SGLT2is in this high-risk population.

KI fragen

Like

Bookmark

Share

View Full Paper

Cite This Study

Chung et al. (Mon,) studied this question.

synapsesocial.com/papers/699e919cf5123be5ed04f44d https://doi.org/https://doi.org/10.1001/jamanetworkopen.2025.60429

KI fragen

Like

Bookmark

Share

View Full Paper